

**DEAR READER,**

This second edition of the BJMO in 2025 once again covers a wide range of topics across the field of oncology.

In the review section, *Eva Donck et al.* provide an overview of the accuracy of **PSMA PET/CT for assessing intraprostatic lesions in patients with prostate cancer**. The authors highlight the promising potential of using the PSMA PET scoring system as a diagnostic tool for these patients. A second **review** provided by *Dr. Sofie Theys et al.* discuss the development of a **supportive tool** for professionals to adequately **refer patients to reliable and accessible support care services in Belgium**.

In the **practice guidelines** section, *Dr. Willem Lybaert et al.* highlight the **vaccine recommendations for patients with solid tumours in Belgium**.

Next, in the **healthcare** section, *Prof. Christophe Matthys et al.* outline the requirement for a **personalised approach to nutrition therapy** for paediatric oncology patients who are malnourished given that malnourishment is now viewed as a modifiable prognostic factor.

Two **oncocases** are also included. One discusses a case of **bilateral tonsillar metastasis** from colorectal adenocarcinoma, underscoring the importance of accurate histopathological assessment, multidisciplinary collaboration, and pharmacogenetic testing in optimising patient outcomes. The other case provides insight into **CDK4/6 inhibitor-induced digoxin intoxication**, highlighting the importance of monitoring digoxin levels and QT intervals when initiating CDK4/6 inhibitors.

Lastly in this issue, a **congress highlights** article from *Dr. Willem Lybaert et al.* provides an in depth discussion of two practice-changing trials in neuroendocrine tumours presented at the **ESMO conference**.

We wish you a pleasant read!

The Publisher